태아치료를 위한 줄기세포의 활용전망
Use of Stem Cell in Fetal Therapy: Current Status and Future Perspectives
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
During the past decades, there has been a great evolution in the field of fetal therapy for congenital defects. Prenatal screening or diagnostic methods including non-invasive and invasive methods and fetal ultrasound have led to earlier and more accurate diagnosis of congenital anomalies. Recent advances in several therapeutic techniques including ultrasound-guided needle therapy, laser therapy or fetal endoscopy, have allowed some fetuses at risk with anatomical defects , to be corrected in utero but still, its clinical indications remain limited. Over the last 30 years, many researchers found usefulness of pluripotent stem cells from amniotic fluid and placenta because they are sources of diverse progenitor cell populations called mesenchymal stem cells. In some human conditions like severe combined immunodeficiency syndrome and chronic granulomatous disease, fetal therapy using stem cell replacement showed some promising results in researches but more studies are required to apply in clinical settings. The aim of this article is to summarize a current status and future perspective of stem cell therapy for treatment of congenital fetal anomalies.
Abstract
During the past decades, there has been a great evolution in the field of fetal therapy for congenital defects. Prenatal screening or diagnostic methods including non-invasive and invasive methods and fetal ultrasound have led to earlier and more accurate diagnosis of congenital anomalies. Recent advances in several therapeutic techniques including ultrasound-guided needle therapy, laser therapy or fetal endoscopy, have allowed some fetuses at risk with anatomical defects , to be corrected in utero but still, its clinical indications remain limited. Over the last 30 years, many researchers found usefulness of pluripotent stem cells from amniotic fluid and placenta because they are sources of diverse progenitor cell populations called mesenchymal stem cells. In some human conditions like severe combined immunodeficiency syndrome and chronic granulomatous disease, fetal therapy using stem cell replacement showed some promising results in researches but more studies are required to apply in clinical settings. The aim of this article is to summarize a current status and future perspective of stem cell therapy for treatment of congenital fetal anomalies.
참고문헌 (39)
- Danzer E, "Fetal surgery for myelomeningocele:progress and perspectives", Dev Med Child Neurol, 54, pp.8~14 (2012)
- David AL, "Gene therapy for the fetus: is there a future?", Best Pract Res Clin Obstet Gynaecol, 22, pp.203~218 (2008)
- David AL, "The current status and future direction of fetal gene therapy", Gene Ther Mol Biol, 7, pp.181~209 (2003)
- De Coppi P, "Isolation of amniotic stem cell lines with potential for therapy", Nat Biotechnol, 25, pp.100~106 (2007)
- Delo DM, "Amniotic fluid and placental stem cells", Methods Enzymol, 419, pp.426~438 (2006)
- Dionigi B, "Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida", J Ped Surg, 50, pp.1037~1041 (2015)
- Ditadi A, "Human and murine amniotic fluid c-kit+Lin-cells display hematopoietic activity", Blood, 113, pp.3953~3960 (2009)
- Di Trapani M, "Immune regulatory properties of cd117 (pos) amniotic fluid stem cells vary according to gestational age", Stem Cells Dev, 24(1), pp.132~143 (2015)
- Fauza DO, "Amniotic fluid and placental stem cells", Best Pract Res Clin Obstet Gynaecol, 18, pp.877~891 (2004)
- Fauza Do, "Fetal tissue engineering: Current state of clinical application", Current Opinion in Pediatrics, 15, pp.267~271 (2003)
- Flake AW, "In utero stem cell transplantation", Best Pract Res Clin Obstet Gynaecol, 18, pp.941~958 (2004)
- Flake Aw, "Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow", N Engl J Med, 335, pp.1806~1810 (1996)
- Fleischman RA, "From white spots to stem cells: the role of the kit receptor in mammalian development", Trends Genet, 9, pp.285~290 (1993)
- Fuchs JR, "Diaphragmatic reconstruction with autologous tendon engineered from mesenchymal amniocytes", J Ped Surg, 39, pp.834~838 (2004)
- Gosden CM, "Amniotic fluid cell types and culture", Br Med Bull, 39, pp.348~354 (1983)
- Jones GN, "Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta", Stem Cells Dev, 23, pp.262~276 (2014)
- Gotherstrom C, "Pre-and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta:a two-center experience", Stem Cells Transl Med, 3, pp.255~264 (2014)
- Kaviani A, "Fetal tissue engineering from amniotic fluid", J Am Coll Surg, 196, pp.592~597 (2003)
- Kaviani A, "The amniotic fluid as a source of cells for fetal tissue engineering", J Pediatr Surg, 36, pp.1662~1665 (2001)
- Michlitsch JG, "Recent advances in bone marrow transplantation in hemoglobinopathies", Curr Mol Med, 8(7), pp.675~689 (2008)
- Moorefield EC, "Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response", PLoS ONE, 6, pp.e26535~ (2011)
- Moschidou D, "Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics", Stem Cells Dev, 22, pp.444~458 (2013)
- Nadri S, "Comparative analysis of mesenchymal stromal cells from murine bone marrow and amniotic fluid", Cytotherapy, 9, pp.729~737 (2007)
- O Donoghue K, "Fetal stem ’ cells", Best Pract Res Clin Obstet Gynaecol, 18, pp.853~875 (2004)
- Ochsenbein-Kölble N, "Inducing proliferation of human amnion epithelial and mesenchymal cells for prospective engineering of membrane repair", J Perinat Med, 31, pp.287~294 (2003)
- Patel M, "Advances in Reprogramming Somatic Cells to Induced Pluripotent Stem Cells", Stem Cell Rev, 6(3), pp.367~380 (2010)
- Pearson EG, "Stem cell and genetic therapies for the fetus", Semin Pediatr Surg, 22, pp.56~61 (2013)
- Peranteau WH, "Evidence for an immune barrier after in utero hematopoietic-cell transplantation", Blood, 109, pp.1331~1333 (2007)
- Perin L, "Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis", PLoS ONE, 5, pp.e9357~ (2010)
- Pipino C, "Placenta as a reservoir of stem cells: an underutilized resource?", Br Med Bull, 105, pp.43~68 (2013)
- Prusa AR, "Amniotic fluid cells and human stem cell research; a new connection", Signature, 8, pp.253~257 (2002)
- RAC, "Regulatory issues: prenatal gene transfer: scientific, medical and ethical issues. A report of the Recombinant DNA Advisory Committee", Hum Gene Ther, 11, pp.1211~1229 (2000)
- Ramachandra DL, "In utero therapy for congenital disorders using amniotic fluid stem cells", Frontiers in Pharmacology, 270(5), pp.1~12 (2014)
- Roubelakis MG, "Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells", Stem Cells Dev, 16, pp.931~952 (2007)
- Shaw SWS, "Autologous transplantation of amniotic fluid derived mesenchymal stem cells into sheep fetuses", Cell Transplant, 20, pp.1015~1031 (2011)
- Tsai MS, "Clonal amniotic fluid-derived stem cells express characteristics of both", Am J Obstet Gynecol, 191, pp.309~314 (2004)
- Walsh DS, "Fetal surgical intervention", Am J Perinat, 17, pp.277~283 (2000)
- Weissman IL, "The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases", Blood, 112(9), pp.3543~3553 (2008)
- Wilson RD, "Present role of stem cells for fetal genetic therapy", J Obstet Gynaecol Can, 27(11), pp.1038~1047 (2005)